trending Market Intelligence /marketintelligence/en/news-insights/trending/Wx7o8ReGE1WJI99eBnK_9Q2 content esgSubNav
In This List

CI Medical posts H2 profit


Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds


Global M&A By the Numbers: Q1 2022


Insight Weekly: Earnings forecasts for US banks; corporate deleveraging; LatAm currency gains


Insight Weekly: M&A slows down; climate tops proxy season; private equity pours into blockchain

CI Medical posts H2 profit

C.I. Medical Co.Ltd. said its normalized net income for the second half was ¥591.3 million.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

Total revenue totaled ¥10.25 billion, and total operating expenses came to ¥9.34 billion.

Reported net income totaled ¥715.0 million, or ¥71.50 per share.

For the year, the company's normalized net income totaled ¥114.06 per share, a gain of 13.4% from ¥100.63 per share in the prior year.

Normalized net income was ¥1.14 billion, a gain of 13.4% from ¥1.01 billion in the prior year.

Full-year total revenue rose 12.1% year over year to ¥20.33 billion from ¥18.14 billion, and total operating expenses rose 11.7% on an annual basis to ¥18.56 billion from ¥16.61 billion.

The company said reported net income increased 17.8% year over year to ¥1.28 billion, or ¥128.20 per share, in the full year, from ¥1.09 billion, or ¥108.80 per share.

As of Feb. 14, US$1 was equivalent to ¥114.11.